Lv61
2460 积分 2024-12-26 加入
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
4小时前
已完结
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
5小时前
已关闭
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
27天前
已完结
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
27天前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
28天前
已完结
Mitigation and management strategies for ocular events associated with tisotumab vedotin
1个月前
已完结
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies
1个月前
已完结
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
1个月前
已完结
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
2个月前
已完结
Frontline therapy of ovarian cancer: trials and tribulations
3个月前
已完结
皖公网安备34019202002308
